<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Drugs available as adjuncts to diet and exercise for treatment of obesity</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Drugs available as adjuncts to diet and exercise for treatment of obesity</h1>
<div class="graphic"><div class="figure"><div class="ttl">Drugs available as adjuncts to diet and exercise for treatment of obesity</div><div class="cntnt"><table cellspacing="0"><colgroup width="15%"></colgroup><colgroup width="35%"></colgroup><colgroup width="15%"></colgroup><colgroup width="35%"></colgroup> <tbody> <tr> <td class="subtitle1">Generic name</td> <td class="subtitle1">Usual dosing (adults)</td> <td class="subtitle1">US DEA schedule</td> <td class="subtitle1">Adverse effects and precautions*</td> </tr> <tr> <td class="subtitle2_left" colspan="4">Pancreatic lipase inhibitor approved for long-term use</td> </tr> <tr> <td class="indent1">Orlistat</td> <td> <p>120 mg 3 times daily with fat-containing meals.</p> A reduced dose of <span class="nowrap_whitespace">60 mg<sup>¶</sup></span> is an option for patients who do not tolerate 120 mg.</td> <td>Not a controlled substance</td> <td> <p>Cramps, flatulence, fecal incontinence, oily spotting, absorption of fat-soluble vitamins may be reduced. Rarely reported: severe liver injury, oxalate-kidney injury.</p> Contraindicated during pregnancy.</td> </tr> <tr> <td class="subtitle2_left" colspan="4">Combination of phentermine-topiramate approved for long-term use</td> </tr> <tr> <td class="indent1">Phentermine-topiramate</td> <td> <p>Initial: 3.75 mg phentermine/23 mg topiramate once daily in the morning for 14 days, followed by 7.5 mg phentermine/46 mg topiramate daily for 12 weeks.</p> Then titrate based upon response: 11.25 mg phentermine/69 mg topiramate daily for 14 days, and then to a maximum dose of 15 mg phentermine/92 mg topiramate once daily.</td> <td>C-IV (due to phentermine component)</td> <td> <p>Dry mouth, taste disturbance, constipation, paraesthesias, depression, anxiety, elevated heart rate, cognitive disturbances, insomnia (higher dose).</p> <p>Abuse potential due to phentermine component.</p> <p>Topiramate is teratogenic (increased risk of oral cleft defects, T1); negative pregnancy test prior to and during treatment and 2 forms of contraception necessary for women of child-bearing potential.</p> <p>Actions of topiramate component include inhibition of carbonic anhydrase; rarely metabolic acidosis and kidney stones may result from renal bicarbonate loss.</p> <p>Maximum dose with moderate hepatic or renal impairment (CrCl &lt;50 mL/min) 7.5 mg phentermine/46 mg topiramate once daily.</p> <p>Upon discontinuation, tapering of dose over at least 1 week using every-other-day dosing is recommended.</p> Contraindicated during pregnancy, hyperthyroidism, glaucoma, patients taking MAO inhibitors.</td> </tr> <tr> <td class="subtitle2_left" colspan="4">Combination of bupropion-naltrexone approved for long-term use</td> </tr> <tr> <td class="indent1">Bupropion-naltrexone</td> <td> <p>Week 1: 1 tablet (8 mg naltrexone/90 mg bupropion) once daily.</p> <p>Week 2: 1 tablet twice daily.</p> <p>Week 3: 2 tablets in morning and one tablet in evening.</p> <p>Week 4: 2 tablets twice daily.</p> Maximum daily dose: 4 tablets (32 mg naltrexone/360 mg bupropion).</td> <td>Not a controlled substance</td> <td> <p>Nausea, constipation, headache, vomiting, dizziness, insomnia, dry mouth.</p> <p>Transient increase in blood pressure (1 to 2 mmHg on average) during initial 12 weeks of treatment; heart rate may also be increased.</p> Contraindicated in patients with uncontrolled hypertension, seizure disorder, eating disorder, use of other bupropion-containing products, chronic opioid use, use within 14 days of MAO inhibitors, pregnancy, or <span class="nowrap_whitespace">breastfeeding.<sup>Δ</sup></span></td> </tr> <tr> <td class="subtitle2_left" colspan="4">GLP-1 agonists approved for long-term use</td> </tr> <tr> <td class="indent1">Liraglutide</td> <td> <p>Initial: 0.6 mg subcutaneously daily.</p> Increase at weekly intervals (1.2, 1.8, 2.4, 3 mg) until recommended dose of 3 mg daily. If increased dose is not tolerated, consider delaying dose escalation by an additional <span class="nowrap_whitespace">week.<sup>◊</sup></span></td> <td rowspan="2">Not controlled substances</td> <td rowspan="2"> <p>Nausea, vomiting, diarrhea, constipation, hypoglycemia in patients with T2DM (more common if used in conjunction with diabetes medications known to cause hypoglycemia), injection site reactions, increased lipase, increased heart rate. Rarely reported: pancreatitis, gallbladder disease, renal impairment, suicidal thoughts.</p> <p>Causes a modest delay of gastric emptying.</p> <p>Advise patients to avoid dehydration in relation to GI side effects.</p> <p>Monitor blood glucose in diabetic patients and adjust co-administered sulfonylureas (eg, reduce dose by 50%) and other anti-diabetic medications as needed to prevent potentially severe hypoglycemia.</p> <p>Possible increase in thyroid cancer risk based on murine model data.</p> <p>Contraindicated in pregnancy and in patients with a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia 2A or 2B.</p> For semaglutide, monitor patients with diabetic retinopathy for eye complications.</td> </tr> <tr> <td class="indent1">Semaglutide</td> <td> <p>Initial: 0.25 mg subcutaneously once weekly.</p> Increase dose at 4-week intervals (0.5, 1, 1.7, 2.4 mg) until recommended dose of 2.4 mg weekly. If increased dose is not tolerated, consider delaying dose escalation by <span class="nowrap_whitespace">4 weeks.<sup>§</sup></span></td> </tr> <tr> <td class="subtitle2_left" colspan="4">Noradrenergic sympathomimetic drugs approved for short-term use</td> </tr> <tr> <td class="indent1">Benzphetamine</td> <td> <p>Initial: 25 mg once daily; may titrate up to 25 to 50 mg one to 3 times daily.</p> Maximum dose: 50 mg 3 times daily.</td> <td>C-III</td> <td rowspan="4">Applies to all sympathomimetic agents: <ul class="decimal_heading"> <li>Due to their side effects and potential for abuse, we suggest <strong>not</strong> prescribing sympathomimetics for weight loss.</li> <li>If prescribed, limit to short-term (≤12 weeks) use.</li> <li>Adverse effects include increase in heart rate, blood pressure, insomnia, dry mouth, constipation, nervousness.</li> <li>Abuse potential due to amphetamine-like effects.</li> <li>May counteract effect of blood pressure medications.</li> <li>Avoid in patients with heart disease, poorly controlled hypertension, pulmonary hypertension, or history of addiction or drug abuse.</li> <li>Contraindicated in patients with a history of CVD, hyperthyroidism, glaucoma, MAO inhibitor-therapy, agitated states, pregnancy, or breast feeding.</li> </ul> </td> </tr> <tr> <td class="indent1">Diethylpropion</td> <td> <p>Immediate release: 25 mg 3 times daily, 1 hour before meals.</p> Controlled release: 75 mg every morning.</td> <td>C-IV</td> </tr> <tr> <td class="indent1">Phentermine</td> <td> <p>Immediate release: 15 to 37.5 mg daily or divided twice daily.</p> <p>Orally disintegrating tablet (ODT): 15 to 37.5 mg once daily in the morning.</p> Immediate release (Lomaira): 8 mg 3 times daily before meals.</td> <td>C-IV</td> </tr> <tr> <td class="indent1">Phendimetrazine</td> <td> <p>Immediate release: 17.5 to 35 mg 2 or 3 times daily, 1 hour before meals.</p> <p>Maximum dose: 70 mg 3 times daily.</p> Sustained release: 105 mg daily in the morning.</td> <td>C-III</td> </tr> </tbody></table></div><div class="graphic_lgnd">Dosing in this table is for adults with normal kidney and liver function. Patients are reevaluated after 12 weeks on the maximum tolerated dose of a weight loss drug to determine efficacy.</div><div class="graphic_footnotes"><p>CrCl: creatinine clearance; CVD: cardiovascular disease (arrhythmias, congestive heart failure, coronary artery disease, stroke, uncontrolled hypertension); GI: gastrointestinal; GLP-1: glucagon-like peptide 1; MAO inhibitors: monamine oxidase inhibitors; T1: first trimester pregnancy; T2DM: type 2 diabetes mellitus; US DEA: United States Drug Enforcement Agency; FDA: US Food and Drug Administration.</p>
<p>* Applies to all drugs except orlistat: May increase risk of hypoglycemia in type 2 diabetics. For additional information on potential interactions of anti-obesity drugs with other medications, use Lexi-Interact program included with UpToDate.</p>
<p>¶ Orlistat 60 mg is available without a prescription in the United States and some other countries.</p>
<p>Δ FDA recommends warning young adults (age 18 to 24 years) of the risk of becoming suicidal during initial treatment of psychiatric disorders with any antidepressant.</p>
<p><span class="lozenge">◊</span> According to United States labeling, if weight loss is not ≥4% after 16 weeks or 3 mg/day is not tolerated, discontinue use. Labeling in the European Union recommends discontinuation of use if weight loss is not ≥5% after 12 weeks of 3 mg/day.</p>
§ According to United States labeling, if 2.4 mg/week is not tolerated, discontinue use.</div><div class="graphic_reference"><p>Courtesy of authors.</p>
With additional data from:
<ol>
<li>The US National Library of Medicine DailyMed website. Availablet at: <a href="https://dailymed.nlm.nih.gov/dailymed/" target="_blank">https://dailymed.nlm.nih.gov/dailymed/</a> (Accessed October 8, 2014).</li>
<li>Kim GW, Lin JE, Blomain ES, Waldman SA. Antiobesity pharmacotherapy: new drugs and emerging targets. Clin Pharmacol Ther 2014; 95:1.</li>
<li>US Food and Drug Administration. FDA approves new drug treatment for chronic weight management, first since 2014. 2021. Available at: <a href="https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-treatment-chronic-weight-management-first-2014" target="_blank">https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-treatment-chronic-weight-management-first-2014</a> (Accessed on June 8, 2021).</li>
</ol></div><div id="graphicVersion">Graphic 86204 Version 21.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
